Our Take
This is vendor content dressed as technical guidance; it correctly identifies real packaging constraints for biologics but stops short of naming the trade-offs between competing vial materials or the actual failure rates that drive adoption.
Why it matters
Biologics now make up 58% of drugs in development (per GlobalData), with mAbs like Keytruda generating $31 billion annually. Manufacturing and storage failures at the vial level directly threaten efficacy and shelf life, making packaging a hard business constraint, not a peripheral detail.
Do this week
Supply chain leads: audit your current vial supplier's elastomer composition (BIMS vs. halobutyl) and container closure integrity test protocols against your drug's E&L profile before scaling manufacturing.
Biologics demand vial systems designed for fragility, not just containment
Large molecule drugs—monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, cell therapies, and mRNA therapeutics—now dominate pharma development and sales. GlobalData reports biologics make up approximately 58% of the drug development pipeline, with mAbs as the leading modality. In 2025, Keytruda (pembrolizumab) generated $31 billion in sales; Dupixent (dupilumab), Skyrizi (risankizumab), and other blockbusters combined for tens of billions more across oncology, inflammatory, and autoimmune indications.
Yet biologics introduce manufacturing and packaging challenges absent in small-molecule drugs. Unlike traditional compounds, large molecules are sensitive to temperature, light, pH, humidity, moisture ingress, and contaminants. These factors degrade the drug product in transit and storage, potentially rendering it ineffective before it reaches the patient.
Vials remain the dominant packaging format for biologics in 2026, despite growing adoption of prefilled syringes and IV bags. Vials offer compatibility with multiple filling lines and sterilization methods (steam and gamma), and they enable lyophilization—a water-removal process that stabilizes biologics under low pressure and freezing temperatures, extending shelf life.
Core vial requirements shift across the drug lifecycle
During manufacturing and storage, the vial's primary function is preventing microbial ingress, gas leakage, and moisture infiltration. Container closure integrity tests evaluate the elastomer stopper's seal reliability. During clinical use, especially for multi-dose formulations, the stopper must allow smooth needle insertion and reseal naturally to protect remaining product from leakage and contamination. This demands penetrability and self-sealing capability in the elastomer, balanced against fragmentation risk—the potential for rubber particles to shed into the drug upon needle penetration.
Extractables and leachables are a silent failure mode
Biologics interact more readily with extractables and leachables (E&L) from rubber stoppers and plastic vials than small molecules do. Additives, stabilizers, or oligomers can migrate from the packaging material into the drug, compromising safety or efficacy. To minimize this risk, manufacturers require inert, high-purity materials. Brominated isobutylene-paramethylstyrene (BIMS) stoppers are cited as the standard for ultra-clean formulations, eliminating rubber oligomers found in typical halobutyl compounds. Some suppliers coat stoppers with fluoropolymer layers to create a barrier between drug and elastomer, reducing E&L risk and eliminating the need for external lubricants such as silicone.
Vial selection is a manufacturing constraint, not an afterthought
The growth of biologics in the pharma pipeline means that vial performance directly impacts time-to-market and commercial supply security. A vial system optimized for one modality may fail for another; E&L profiles vary by drug chemistry, and lyophilization stress tests the stopper's durability. Regulatory filings require container closure integrity data and extractables testing, making vial qualification a rate-limiting step in preclinical and clinical manufacturing.
Supply chain disruptions, material shortages, and supplier capacity constraints in specialty vial manufacturing have already caused delays in biologic launches. As mAb and cell-therapy pipelines accelerate, demand for compatible, high-purity vial systems will grow faster than capacity in many regions.
What to evaluate in your vial supplier
When selecting a vial system for a biologic candidate, confirm the elastomer compound used in the stopper and request independent E&L data (not just vendor claims) for your specific drug. Validate container closure integrity protocols against your stability timeline and storage conditions. For multi-dose formulations, request fragmentation testing data. Understand whether coated stoppers are necessary for your formulation or whether standard BIMS stoppers suffice—coating adds cost and manufacturing complexity. Finally, assess supplier capacity and lead times; many specialty vial suppliers are operating near capacity, and long-term supply agreements should be negotiated early in development.